Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
Clayton AH, Kingsberg SA, Portman DJ, et al.
The Journal of Sexual Medicine, 2021 · n = 234
Key finding
Long-term bremelanotide maintained therapeutic response (71% sustained improvement) with no new safety signals over 52 weeks of continued use.
Summary
Open-label extension of Phase 3 trials assessing long-term safety, efficacy, and tolerability of continuing bremelanotide beyond 12 weeks.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
Skin Hyperpigmentation with Melanocortin-4 Receptor Agonists: Predictors and Prevention
The Journal of Sexual Medicine · 2020 · Human Pilot